Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay

Credo Diagnostics Biomedical Pte. Ltd.1,268 enrolled

Overview

The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population. The primary aim is to determine the PPA/NPA against a comparator assay. The secondary aim is to determine the diagnostic sensitivity, specificity, PPV and NPV against the standard-of-care test. Each subjects will be asked to provide both nasal swab (NS) and nasopharyngeal swab (NPS) for testing purposes.

The study is designed as a multisite, observational, prospective study. Subjects will be prospectively recruited from the target population, specifically individuals displaying signs and/or symptoms of respiratory tract infections. Consent for participation will be obtained prior to any eligibility confirmation or sample collection. Subsequently, both nasal swab (NS) and nasopharyngeal swab (NPS) specimens will be collected from each subject. These specimens will be tested using both the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay and the Cepheid Xpert Xpress CoV-2/Flu/RSV plus assay (comparator) to determine the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA). Subjects will be recruited across up to 20 sites, targeting the following intended user groups: Trained laboratory professionals in a central laboratory setting Trained healthcare practitioners in a point-of-care (POC) setting under CLIA moderate and high complexity. If a standard-of-care (SOC) diagnosis is available, the sensitivity, specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) will also be calculated.

Study Type

OBSERVATIONAL

Enrollment

1,268

Conditions

SARS-CoV-2 COVID-19 RSV

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subject displaying one or more of the following signs and/or symptoms of a respiratory tract infection: 1. Fever 2. Cough 3. Nasal Congestion 4. Shortness of breath 5. Difficulty in breathing 6. Runny nose 7. Sore throat 8. Muscle pain 9. Headache 10. Chills 11. Nausea 12. Diarrhoea 13. Vomiting 14. New loss of taste/smell * If age 18 or over, subject is willing and capable of providing written informed consent. If under the age of 18, parent or legal guardian is willing to and capable of providing consent/assent. Assent should be obtained from minor subjects of appropriate intellectual age as defined by the IRB. Exclusion Criteria: * Subject is unable to provide consent and assent (as appropriate) or parental/legal guardian consent permission and assent (as appropriate) cannot be obtained. * PI determines that specimen collection represents an unacceptable risk. * Subjects who have already been enrolled in the study previously.

Outcomes

Primary Outcomes

Positive percent agreement(PPA) and Negative percent agreement (NPA)

Positive percent agreement(PPA) and Negative percent agreement (NPA) between the VitaSIRO solo™ SARS-CoV-2/Flu/RSV and Cepheid Xpert® Xpress CoV-2/Flu/RSV plus assay

Time frame: In 7 days after specimen collection

Secondary Outcomes

Comparison to SOC testing

Evaluation of Diagnostic Performance Metrics for the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay: Sensitivity, Specificity, PPV, and NPV Using Nasal and Nasopharyngeal Swabs Compared to Standard-of-Care Diagnostics

Time frame: In 7 Days after specimen collection